| Hormonal aspects of overtraining syndrome: a systematic review FA Cadegiani, CE Kater BMC Sports Science, Medicine and Rehabilitation 9 (1), 1-15, 2017 | 127 | 2017 |
| Hypothalamic-pituitary-adrenal (HPA) axis functioning in overtraining syndrome: findings from endocrine and metabolic responses on overtraining syndrome (EROS)—EROS-HPA Axis FA Cadegiani, CE Kater Sports medicine-open 3 (1), 1-11, 2017 | 62 | 2017 |
| Body composition, metabolism, sleep, psychological and eating patterns of overtraining syndrome: results of the EROS study (EROS-PROFILE) FA Cadegiani, CE Kater Journal of sports sciences 36 (16), 1902-1910, 2018 | 60 | 2018 |
| Adrenal fatigue does not exist: a systematic review FA Cadegiani, CE Kater BMC endocrine disorders 16 (1), 1-16, 2016 | 51 | 2016 |
| Novel insights of overtraining syndrome discovered from the EROS study FA Cadegiani, CE Kater BMJ Open Sport & Exercise Medicine 5 (1), e000542, 2019 | 48 | 2019 |
| Basal hormones and biochemical markers as predictors of overtraining syndrome in male athletes: the EROS-BASAL study FA Cadegiani, CE Kater Journal of athletic training 54 (8), 906-914, 2019 | 47 | 2019 |
| Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a randomized, double … FA Cadegiani, J McCoy, CG Wambier, S Vaño-Galván, J Shapiro, A Tosti, ... Cureus 13 (2), 2021 | 44 | 2021 |
| Early antiandrogen therapy with dutasteride reduces viral shedding, inflammatory responses, and Time-to-Remission in males with COVID-19: a randomized, double-blind, placebo … FA Cadegiani, J McCoy, CG Wambier, A Goren Cureus 13 (2), 2021 | 44 | 2021 |
| Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. A Goren, CG Wambier, S Herrera, J McCoy, S Vaño-Galván, F Gioia, ... Wiley, 2021 | 44 | 2021 |
| Novel causes and consequences of overtraining syndrome: the EROS-DISRUPTORS study FA Cadegiani, CE Kater BMC Sports Science, Medicine and Rehabilitation 11 (1), 1-13, 2019 | 40 | 2019 |
| 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J McCoy, FA Cadegiani, CG Wambier, S Herrera, S Vaño-Galván, ... Wiley, 2021 | 39 | 2021 |
| Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS) FA Cadegiani, A Goren, CG Wambier Medical Hypotheses 143, 110112, 2020 | 39 | 2020 |
| Repurposing existing drugs for COVID-19: an endocrinology perspective FA Cadegiani BMC Endocrine Disorders 20 (1), 1-19, 2020 | 37 | 2020 |
| Clinical and biochemical characteristics of high-intensity functional training (HIFT) and overtraining syndrome: findings from the EROS study (The EROS-HIFT) FA Cadegiani, CE Kater, M Gazola Journal of sports sciences 37 (11), 1296-1307, 2019 | 36 | 2019 |
| Hormonal response to a non-exercise stress test in athletes with overtraining syndrome: results from the endocrine and metabolic responses on Overtraining syndrome (EROS)—EROS … FA Cadegiani, CE Kater Journal of Science and Medicine in Sport 21 (7), 648-653, 2018 | 35 | 2018 |
| Clinical symptoms of hyperandrogenic women diagnosed with COVID-19 FA Cadegiani, RK Lim, A Goren, J McCoy, M Situm, M Kovacevic, ... WILEY, 2020 | 33 | 2020 |
| Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension? FA Cadegiani American Journal of Physiology-Endocrinology and Metabolism 318 (5), E587-E588, 2020 | 33 | 2020 |
| Spironolactone: an anti-androgenic and anti-hypertensive drug that may provide protection against the novel coronavirus (SARS-CoV-2) induced acute respiratory distress syndrome … FA Cadegiani, CG Wambier, A Goren Frontiers in medicine 7, 453, 2020 | 32 | 2020 |
| Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. J McCoy, CG Wambier, S Herrera, S Vaño-Galván, F Gioia, B Comeche, ... Journal of the European Academy of Dermatology and Venereology: JEADV 35 (1 …, 2021 | 30 | 2021 |
| Proxalutamide reduces the rate of hospitalization for COVID-19 male outpatients: a randomized double-blinded placebo-controlled trial J McCoy, A Goren, FA Cadegiani, S Vaño-Galván, M Kovacevic, M Situm, ... Frontiers in medicine, 1043, 2021 | 29* | 2021 |
